Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House

Executive Summary

With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.

You may also be interested in...



Cosmetics Reg Reform Ill-Situated As Trump, FDA Explore 'Burden Reduction'

Any movement to advance proposed cosmetics reform legislation could be seen as running counter to President Trump's executive orders earlier this year, which now have FDA centers seeking "broad public comment" on how to achieve "meaningful burden reduction."

Got Ideas For Reducing Industry's Regulatory Burden? FDA Wants To Know

CFSAN and other FDA centers ask for "broad public comment" the agency will use "to guide our initial review of our regulations" required in President Trump's January executive order for federal agencies to "evaluate existing regulations and identify those that may merit repeal, replacement, or modification."

OTC Monograph Reform, User Fee Legislation Coming 'Any Day' – CHPA

Imminent OTC monograph reform legislation signals an agreement between industry and FDA on details of a proposal, which also includes a potential user fee program. CHPA also is hopeful for legislation restoring direct OTC drug purchases with pre-tax savings accounts.

Related Content

Topics

UsernamePublicRestriction

Register

PS119509

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel